Nicholas Investment Partners’s Ginkgo Bioworks DNA Stock Holding History

Nicholas Investment Partners’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,415	Closed	-$390K	–	207
2024 Q1	$390K	Hold	8,415	–	–	0.04%	196
2023 Q4	$569K	Hold	8,415	–	–	0.07%	169
2023 Q3	$609K	Hold	8,415	–	–	0.05%	168
2023 Q2	$626K	Hold	8,415	–	–	0.04%	171
2023 Q1	$448K	Sell	8,415 -3,654	-30%	-$232K	0.03%	179
2022 Q4	$816K	Hold	12,069	–	–	0.07%	157
2022 Q3	$1.51M	Hold	12,069	–	–	0.14%	135
2022 Q2	$1.15M	Hold	12,069	–	–	0.11%	146
2022 Q1	$1.95M	Sell	12,069 -28,756	-70%	-$5.6M	0.14%	150
2021 Q4	$13.6M	Sell	40,825 -18,707	-31%	-$8.89M	0.86%	35
2021 Q3	$27.6M	Buy	+59,532	New	+$29M	2.01%	3

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Nicholas Investment Partners's DNA Position: Q2 2024 in Review

Nicholas Investment Partners sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 8,415 shares — an estimated $390K sold.

Nicholas Investment Partners first reported a position in DNA in Q3 2021 and held it in 11 quarters. The position peaked at $27.6M in Q3 2021. 312 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

Nicholas Investment Partners reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
Nicholas Investment Partners sold 8,415 Ginkgo Bioworks shares in Q2 2024, an estimated $390K.
Nicholas Investment Partners first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 11 quarters.
Nicholas Investment Partners's Ginkgo Bioworks position peaked at $27.6M in Q3 2021.
312 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Nicholas Investment Partners's 13F filing for Q2 2024, filed 8 Aug 2024.